Pembrolizumab has been approved as a first-line treatment for PD-L1-positive R/M HNSCC and in combination with chemotherapy for patients with any PD-L1 status since the results of the KEYNOTE-048 trial came out in 2019 [168]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.